Literature DB >> 4451346

Characteristics of the in vitro inhibition of arenavirus synthesis by bis-benzimidazoles.

J P Stella, K D Yankaskas, J H Morgan, M P Fox, C J Pfau.   

Abstract

The dihydrochloride salt of (S,S)-1,2-bis(5-methoxy-2-benzimidazolyl)-1,2-ethandiol (A37536) inhibits the synthesis of lymphocytic choriomeningitis (LCM), Parana, and Pichinde viruses in L-929 cells. The compound has no direct inactivating effect on LCM virus nor does it affect the adsorption of LCM virus to L cells. The drug-cell interaction is slow. Maximal activity is observed only by exposing cells to the drug at least 8 h prior to LCM virus infection, or by concomitant drug treatment and infection at a low multiplicity. Addition of serum-free media to L cells after LCM virus infection diminishes the activity of A37536. Whereas A37536 exhibits its antiviral activity at concentrations that have little or no effect on L cell division rate, a marked change can be noted in the cell's sensitivity to lysis by standard trypsin dispersal procedures. A37536 has no specific antiviral activity in LCM virus-infected BHK, HeLa, or Vero cells. All of the four tested derivatives of A37536 showed antiviral activity against LCM virus but only at concentrations that reduced the growth rate or were toxic to L cells.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4451346      PMCID: PMC444730          DOI: 10.1128/AAC.6.6.747

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Differences in the selective virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine HCl.

Authors:  I TAMM; H J EGGERS
Journal:  Virology       Date:  1962-11       Impact factor: 3.616

2.  Effect of chloroquine on the growth of animal viruses.

Authors:  Y Shimizu; S Yamamoto; M Homma; N Ishida
Journal:  Arch Gesamte Virusforsch       Date:  1972

3.  Bisbenzimidazoles. Potent inhibitors of rhinoviruses.

Authors:  W R Roderick; C W Nordeen; A M Von Esch; R N Appell
Journal:  J Med Chem       Date:  1972-06       Impact factor: 7.446

4.  Chloroquine: protection against virus-induced cell damage without inhibition of virus growth.

Authors:  D E Wilson
Journal:  J Gen Virol       Date:  1972-01       Impact factor: 3.891

5.  Plaque size heterogeneity: a genetic trait of lymphocytic choriomeningitis virus.

Authors:  A J Pulkkinen; C J Pfau
Journal:  Appl Microbiol       Date:  1970-07

6.  Inhibitory effect of 1,2-bis(2-benzimidazolyl)-1,2-ethanediol derivatives on poliovirus.

Authors:  S Akihama; M Okude; K Sato; S Iwabuchi
Journal:  Nature       Date:  1968-02-10       Impact factor: 49.962

7.  Inhibition of lymphocytic choriomeningitis virus multiplication by 2-(alpha-hydroxybenzyl)benzimidazole.

Authors:  C J Pfau; K P Camyre
Journal:  Virology       Date:  1968-07       Impact factor: 3.616

8.  Pichindé virus, a new virus of the Tacaribe group from Colombia.

Authors:  H Trapido; C Sanmartín
Journal:  Am J Trop Med Hyg       Date:  1971-07       Impact factor: 2.345

9.  Inhibition of influenza virus multiplication by alkyl derivatives of benzimidazole. III. Relationship between inhibitory activity and chemical structure.

Authors:  I TAMM; K FOLKERS; C H SHUNK; D HEYL; F L HORSFALL
Journal:  J Exp Med       Date:  1953-09       Impact factor: 14.307

10.  Antiviral activity of a bis-benzimidazole against experimental rhinovirus infections in chimpanzees.

Authors:  N L Shipkowitz; R R Bower; J B Schleicher; F Aquino; R N Appell; W R Roderick
Journal:  Appl Microbiol       Date:  1972-01
View more
  2 in total

1.  Arenavirus chemotherapy--retrospect and prospect.

Authors:  C J Pfau
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

2.  Evaluation of bis-benzimidazoles in the treatment of murine lymphocytic choriomeningitis virus infections.

Authors:  J P Stella; J Michaelson; S L Dorfman; J H Morgan; C J Pfau
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.